Few neoplastic diseases have undergone a transformation in a relatively short period like
chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoietic
stem cells. At the molecular level, the disorder results from t (9; 22)(q34; q11) reciprocal …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …

The progress made in the understanding of chronic myeloid leukemia (CML) since the
recognition of a common chromosomal abnormality to the introduction of ever more effective …

Clinical management guidelines on malignant disorders are generally based on data from
clinical trials with selected patient cohorts. In Sweden, more than 95% of all patients …

Tyrosine-kinase inhibitors have changed the natural history of chronic myeloid leukaemia in
such a way that patients with adequate access to these agents, who are properly managed …

The introduction of tyrosine kinase inhibitors (TKI) in the treatment of Philadelphia
chromosome-positive (Ph+) chronic myeloid leukemia (CML) has revolutionized the …

Patients diagnosed with chronic myeloid leukemia (CML) and treated with BCR-ABL1
tyrosine kinase inhibitors (TKIs) have long life spans. Selection of an appropriate first-line …

The Sokal and Hasford scores were developed in the chemotherapy and interferon era and
are widely used as prognostic indicators in patients with chronic myeloid leukemia (CML) …

Prognostic risk scores are used to predict survival at diagnosis in patients with chronic
myeloid leukemia (CML) presenting in chronic phase. Until recently, risk stratification of CML …